Literature DB >> 29018297

Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease.

Martin Paspe Cruz.   

Abstract

Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson's disease.

Entities:  

Year:  2017        PMID： 29018297      PMCID： PMC5614412     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  14 in total

1.  Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors:  Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

2.  Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

Authors:  G Fénelon; F Mahieux; R Huon; M Ziégler
Journal:  Brain       Date:  2000-04       Impact factor: 13.501

Review 3.  Safinamide: first global approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

4.  Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants.

Authors:  P Pevarello; A Bonsignori; C Caccia; R Amici; R A McArthur; R G Fariello; P Salvati; M Varasi
Journal:  Bioorg Med Chem Lett       Date:  1999-09-06       Impact factor: 2.823

5.  Longitudinal outcome of Parkinson's disease patients with psychosis.

Authors:  S A Factor; P J Feustel; J H Friedman; C L Comella; C G Goetz; R Kurlan; M Parsa; R Pfeiffer
Journal:  Neurology       Date:  2003-06-10       Impact factor: 9.910

6.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

7.  Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.

Authors:  Sonja Krösser; Anne Marquet; Dieter Gallemann; Peter Wolna; Nicolas Fauchoux; Robert Hermann; Andreas Johne
Journal:  Biopharm Drug Dispos       Date:  2012-11-19       Impact factor: 1.627

Review 8.  Epidemiology of psychosis in Parkinson's disease.

Authors:  Gilles Fénelon; Guido Alves
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

9.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Authors:  Jeffrey Cummings; Stuart Isaacson; Roger Mills; Hilde Williams; Kathy Chi-Burris; Anne Corbett; Rohit Dhall; Clive Ballard
Journal:  Lancet       Date:  2013-11-01       Impact factor: 79.321

10.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321
View more
  2 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

Review 2.  Four main therapeutic keys for Parkinson's disease: A mini review.

Authors:  Daniel Hernandez-Baltazar; Rasajna Nadella; Laura Mireya Zavala-Flores; Christian de Jesús Rosas-Jarquin; María de Jesús Rovirosa-Hernandez; Arnulfo Villanueva-Olivo
Journal:  Iran J Basic Med Sci       Date:  2019-07       Impact factor: 2.699
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.